VEGF-A i PDGF-BB — czynniki angiogenne a stopień zaawansowania zespołu stopy cukrzycowej

Abstract

Introduction: In patients with diabetic foot syndrome (DFS), an inadequate angiogenic response is observed. The aim of this study was to evaluate the concentrations of VEGF-A, PDGF-BB, sVEGF-R2 and sVEGF-R1 in patients with diabetes-complicated diabetic foot syndrome and analyse them using selected clinical data. Material and methods: Forty seven diabetic patients, 25 women mean age 63 and 20 men mean age 60.5, with diabetic foot syndrome (DFS) were enrolled in the experimental group. To evaluate angiogenesis factors depending on Wagner grade, the subjects were divided into three subgroups: I -patients with 0 Wagner grade (n = 14); II -patients with 1,2,3 Wagner grades (n = 15); and III -patients with 4,5 Wagner grades (n = 18). The control group consisted of 20 healthy volunteers. The material for research was blood. In this study, a strong positive correlation between VEGF-A and PDGF-BB was observed (R = 0.66; p = 0.000001). Conclusions: Our study revealed that proangiogenic factor levels were increased in DFS. This is associated with lower limb ischaemia and hypoxic conditions. The stage of diabetic foot syndrome advancement influenced VEGF-A and PDGF-BB concentrations.

Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease

“…Similar results (versus the control group), i.e. decreased mean concentrations of sVEGFR-2 in patients with DFS, were achieved by Drela et al (2014). No significant differences in the serum concentration of (s)VEGFR1 or (s)VEGFR-2 were observed by Ruszkowska-Ciastek et al (2014) between the subjects with diabetes and the control group.…”

“…Yet Zakareia (2012) observed much higher plasma VEGF levels in subjects with diabetes and PAD. In the study on patients with the DFS, Drela et al (2014) reported significantly higher VEGF-A concentrations in patients with type 2 diabetes. Ruszkowska-Ciastek et al (2014) observed nonsignificant differences in the serum concentrations of VEGF-A between the patients with well-controlled diabetes and the control group.…”

“…Additionally, VEGF-A mobilizes endothelial progenitor cells (EPCs) which migrate to ischemic tissues, where they differentiate to endothelial cells and proliferate rapidly (Bao et al, 2009). As clinical and laboratory data indicate, impaired angiogenesis can be observed in, for example, patients with diabetic foot syndrome (DFS) (Drela et al, 2014). Therefore, it is necessary to investigate factors that have an influence on angiogenesis in PAD and diabetes alike.…”

MicroRNA‑22 alleviates inflammation in ischemic stroke via p38 MAPK pathways

“…All can catalyze arginine (Arg) to synthesize NO (9). Under physiological conditions, NO content in the brain tissue is low and mainly catalyzed by nNOS (10,11). NO is involved in in the signal transduction and synaptic plasticity of the nervous system.…”

“…However, under pathological conditions, including cerebral infarction, cerebral hemorrhage, brain injury and epilepsy (9), brain tissue generates a large amount of NO, which inhibits the activity of neuronal mitochondrial cytochrome oxidase. As a result, the synthesis of ATP is reduced, leading to excessive neuronal depolarization (11).…”